Independent
Tenure on this board
2.4 yrs
Also a director at
Natera Inc (NTRA)Rapport Therapeutics Inc (RAPP)Bioage Labs Inc (BIOA)Seaport Therapeutics Inc (SPTX)
3 nominees · 2 ballot items.
Election of three directors for three-year terms; Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026.
Elect three directors (James Healy, M.D., Ph.D.; John Hohneker, M.D.; and Stuart Lutzker, M.D., Ph.D.) to the board for three-year terms expiring in 2029.
Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
The proposal asks shareholders to ratify the audit committee’s appointment of PricewaterhouseCoopers LLP as ArriVent’s independent registered public accounting firm for fiscal year 2026. Management and the audit committee selected PwC after reviewing independence considerations and commercial relationships and concluded PwC’s independence is uncompromised. The company frames this vote as a governance check—seeking shareholder input though the audit committee retains the discretion to change auditors if needed. Context includes a transition from KPMG to PwC earlier in 2025 and disclosure of audit fees and services rendered; the audit committee has pre-approval processes for audit and non-audit services. The board recommends a vote FOR the ratification, stating that such ratification reflects good corporate governance, and notes that failure to ratify would prompt reconsideration by the audit committee. Given auditor independence was evaluated and PwC has billed audit fees for 2025, the proposal is routine but important for oversight; institutional investors typically support auditor ratification unless there are known independence concerns.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 9.4% | 4,401,083 | $102M |
| 2 | INFINITUM ASSET MANAGEMENT, LLC | 8.9% | 4,148,923 | $96M |
| 3 | HHLR ADVISORS, LTD. | 8.4% | 3,929,117 | $91M |
| 4 | ORBIMED ADVISORS LLCActivist | 6.5% | 3,027,328 | $70M |
| 5 | FMR LLC | 5.5% | 2,567,522 | $59M |
| 6 | Octagon Capital Advisors LP | 4.2% | 1,971,054 | $45M |
| 7 | Novo Holdings A/S | 4.2% | 1,942,142 | $45M |
| 8 | Sofinnova Investments, Inc. | 3.6% | 1,696,752 | $39M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 1,528,893 | $35M |
| 10 | General Catalyst Group Management, LLC | 3.2% | 1,494,786 | $34M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.